• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Complex karyotype in unfit patients with CLL treated with ibrutinib and rituximab: the GIMEMA LLC1114 phase 2 study.

作者信息

Rigolin Gian Matteo, Del Giudice Ilaria, Bardi Antonella, Melandri Aurora, García-Jacobo Rocio Edith, Cura Francesca, Raponi Sara, Ilari Caterina, Cafforio Luciana, Piciocchi Alfonso, Arena Valentina, Reda Gianluigi, Albano Francesco, Molica Stefano, Sportoletti Paolo, Trentin Livio, Marchetti Monia, Nanni Mauro, Peragine Nadia, Mariglia Paola, Vignetti Marco, Guarini Anna, Mauro Francesca Romana, Foà Robin, Cuneo Antonio

机构信息

Hematology Section, St Anna University Hospital, Ferrara, Italy.

Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy.

出版信息

Blood. 2021 Dec 23;138(25):2727-2730. doi: 10.1182/blood.2021011883.

DOI:10.1182/blood.2021011883
PMID:34587233
Abstract
摘要

相似文献

1
Complex karyotype in unfit patients with CLL treated with ibrutinib and rituximab: the GIMEMA LLC1114 phase 2 study.依鲁替尼和利妥昔单抗治疗的不适合的慢性淋巴细胞白血病患者的复杂核型：GIMEMA LLC1114 2期研究
Blood. 2021 Dec 23;138(25):2727-2730. doi: 10.1182/blood.2021011883.
2
Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study.苯达莫司汀和利妥昔单抗在未经治疗的先前不适合的慢性淋巴细胞白血病患者中的疗效。在真实环境中与伊布替尼的间接比较。一项 GIMEMA-ERIC 和美国的研究。
Cancer Med. 2020 Nov;9(22):8468-8479. doi: 10.1002/cam4.3470. Epub 2020 Sep 24.
3
[Current diagnosis and treatment of chronic lymphocytic leukaemia].[慢性淋巴细胞白血病的当前诊断与治疗]
Dtsch Med Wochenschr. 2020 Aug;145(16):1139-1144. doi: 10.1055/a-1039-8472. Epub 2020 Aug 13.
4
Ibrutinib induces durable remissions in treatment-naïve patients with CLL and 17p deletion and/or TP53 mutations.依鲁替尼可使初治的慢性淋巴细胞白血病（CLL）且伴有17p缺失和/或TP53突变的患者获得持久缓解。
Blood. 2021 Dec 16;138(24):2589-2592. doi: 10.1182/blood.2021012315.
5
Ibrutinib as initial therapy in chronic lymphocytic leukemia: A systematic review and meta-analysis.伊布替尼作为慢性淋巴细胞白血病的初始治疗：一项系统评价和荟萃分析。
Eur J Haematol. 2020 May;104(5):512-515. doi: 10.1111/ejh.13387. Epub 2020 Feb 22.
6
A Prospective Economic Analysis of Early Outcome Data From the Alliance A041202/ CCTG CLC.2 Randomized Phase III Trial Of Bendamustine-Rituximab Compared With Ibrutinib-Based Regimens in Untreated Older Patients With Chronic Lymphocytic Leukemia.联盟 A041202/CCTG CLC.2 前瞻性经济分析：随机 III 期试验结果，比较苯达莫司汀-利妥昔单抗与伊布替尼方案治疗未经治疗的老年慢性淋巴细胞白血病患者。
Clin Lymphoma Myeloma Leuk. 2021 Nov;21(11):766-774. doi: 10.1016/j.clml.2021.06.011. Epub 2021 Jul 3.
7
Real-World Treatment Patterns, Adverse Events, Resource Use, and Costs Among Commercially Insured, Younger Patients with Chronic Lymphocytic Leukemia in the USA: A Retrospective Cohort Study.美国商业保险覆盖的年轻慢性淋巴细胞白血病患者的真实世界治疗模式、不良事件、资源利用和成本：一项回顾性队列研究。
Adv Ther. 2020 Jul;37(7):3129-3148. doi: 10.1007/s12325-020-01350-w. Epub 2020 May 12.
8
Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial.乌布利昔单抗联合伊布替尼与伊布替尼单药治疗复发或难治性高危慢性淋巴细胞白血病患者（GENUINE）：一项 3 期、多中心、开放标签、随机试验。
Lancet Haematol. 2021 Apr;8(4):e254-e266. doi: 10.1016/S2352-3026(20)30433-6. Epub 2021 Feb 22.
9
Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study.依鲁替尼联合利妥昔单抗与安慰剂联合利妥昔单抗治疗华氏巨球蛋白血症的随机 III 期 iNNOVATE 研究的最终分析。
J Clin Oncol. 2022 Jan 1;40(1):52-62. doi: 10.1200/JCO.21.00838. Epub 2021 Oct 4.
10
[Aspergillus spondylodiscitis in a patient treated with ibrutinib].[接受伊布替尼治疗的患者发生曲霉性脊椎间盘炎]
Med Mal Infect. 2020 May;50(3):296-297. doi: 10.1016/j.medmal.2019.10.007. Epub 2019 Nov 10.

引用本文的文献

1
Chromoanagenesis Detection in Chronic Lymphocytic Leukemia.慢性淋巴细胞白血病中的染色体混乱检测
Methods Mol Biol. 2025;2968:231-248. doi: 10.1007/978-1-0716-4750-9_13.
2
Management strategies for patients with chronic lymphocytic leukaemia harbouring complex karyotype.伴有复杂核型的慢性淋巴细胞白血病患者的管理策略
Br J Haematol. 2025 Mar;206(3):832-841. doi: 10.1111/bjh.19986. Epub 2025 Jan 6.
3
Outcomes and prognostic factors in 3306 patients with relapsed/refractory chronic lymphocytic leukemia treated with ibrutinib outside of clinical trials: A nationwide study.
3306例在临床试验之外接受依鲁替尼治疗的复发/难治性慢性淋巴细胞白血病患者的结局及预后因素：一项全国性研究
Hemasphere. 2024 Oct 8;8(10):e70017. doi: 10.1002/hem3.70017. eCollection 2024 Oct.
4
Chronic Lymphocytic Leukemia: Prognostic Factors in the Era of Novel Drugs.慢性淋巴细胞白血病：新药时代的预后因素
Cancers (Basel). 2024 Jul 31;16(15):2732. doi: 10.3390/cancers16152732.
5
Utility of Targeted Sequencing Compared to FISH for Detection of Chronic Lymphocytic Leukemia Copy Number Alterations.与荧光原位杂交（FISH）相比，靶向测序在检测慢性淋巴细胞白血病拷贝数改变方面的效用
Cancers (Basel). 2024 Jul 3;16(13):2450. doi: 10.3390/cancers16132450.
6
Complex Karyotype Detection in Chronic Lymphocytic Leukemia: A Comparison of Parallel Cytogenetic Cultures Using TPA and IL2+DSP30 from a Single Center.慢性淋巴细胞白血病复杂核型检测：来自单一中心的使用TPA和IL2 + DSP30的平行细胞遗传学培养比较
Cancers (Basel). 2024 Jun 18;16(12):2258. doi: 10.3390/cancers16122258.
7
First-Line Treatment of Older Patients with CLL: A New Approach in the Chemo-Free Era.老年慢性淋巴细胞白血病患者的一线治疗：无化疗时代的新方法。
Cancers (Basel). 2023 Jul 29;15(15):3859. doi: 10.3390/cancers15153859.
8
Genomic profiling for clinical decision making in lymphoid neoplasms.淋巴肿瘤临床决策的基因组分析。
Blood. 2022 Nov 24;140(21):2193-2227. doi: 10.1182/blood.2022015854.